1,500
Participants
Start Date
January 31, 2016
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
Bortezomib
bortezomib was administered follow the doctor's advice.
Eltrombopag
eltrombopag was administered follow the doctor's advice.
Imatinib
imatinib was administered follow the doctor's advice.
dasatinib
dasatinib was administered follow the doctor's advice.
Pegaspargase
pegaspargase was administered follow the doctor's advice.
Anti-Infective Drugs
anti-infective drugs was administered follow the doctor's advice.
PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
pegaspargase was administered follow the doctor's advice.
COMPLETED
Department of Pediatrics, the Affiliated Hospital of Xuzhou Medical University, Xuzhou
RECRUITING
State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tanjin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER
Wei Zhao
OTHER